{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:35:49Z","timestamp":1794540949660,"version":"4.9.1"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>\n                      Development of molecular therapies for liver fibrosis is slowed by a lack of noninvasive methods addressing questions of target expression, target engagement, and treatment response. Integrin \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>6<\/jats:sub>\n                      is a biomarker of liver fibrosis that is upregulated in livers of patients with primary sclerosing cholangitis. It activates latent TGF-\u03b2 and plays a critical role in regulating extracellular matrix expression, especially collagen. In this study, our aim was to use combined \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>6<\/jats:sub>\n                      integrin-targeted positron emission tomography (PET) and collagen-specific magnetic resonance imaging (MRI) to measure target expression\/engagement and liver fibrosis reduction with a \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>6<\/jats:sub>\n                      integrin inhibitor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      We conducted a treatment study in bile duct\u2013ligated (BDL) rats using a small molecule inhibitor to \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>6<\/jats:sub>\n                      \/\u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>1<\/jats:sub>\n                      .\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTA-R01-MG, an \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>6<\/jats:sub>\n                      -specific PET probe, was used to noninvasively measure \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>6<\/jats:sub>\n                      expression and target engagement in the liver. CM-101, a type I collagen MRI probe, was used to quantify fibrosis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      <jats:sup>68<\/jats:sup>\n                      Ga-DOTA-R01-MG PET showed 3-fold higher liver uptake in BDL rats compared with sham rats at 17\u2009days after surgery. Pretreatment with high dose \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>6<\/jats:sub>\n                      \/\u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>1<\/jats:sub>\n                      inhibitor 1 hour before imaging significantly decreased liver PET uptake in BDL rats (31%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.012). Two weeks of daily dosing with an \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>6<\/jats:sub>\n                      \/\u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>1<\/jats:sub>\n                      inhibitor attenuated \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>6<\/jats:sub>\n                      expression in BDL rat liver as assessed by \u03b1\n                      <jats:sub>v<\/jats:sub>\n                      \u03b2\n                      <jats:sub>6<\/jats:sub>\n                      PET (0.27\u2009\u00b1\u20090.07 percent injected dose [%ID]\/mL compared with 0.40\u2009\u00b1\u20090.09 %ID\/mL in vehicle-treated group,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.014) and reduced liver fibrosis as assessed by collagen MRI (liver relaxation rate change \u0394R\n                      <jats:sub>1<\/jats:sub>\n                      \u2009=\u20090.14\u2009\u00b1\u20090.11 vs 0.36\u2009\u00b1\u20090.06,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0037). Imaging findings were confirmed by histology (collagen proportionate area 10.7\u2009\u00b1\u20092.8% vs 22.5\u2009\u00b1\u20096.1%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A single imaging protocol combining molecular MRI and PET can be used to effectively monitor integrin inhibitor treatment by measuring target expression\/engagement and treatment outcomes. Multimodality molecular imaging may be valuable in accelerating drug development in molecular therapies for liver fibrosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rli.0000000000001202","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T03:27:35Z","timestamp":1746070055000},"page":"59-67","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Multimodal Imaging Demonstrates Antifibrotic Effects of Targeting \u03b1v\u03b26\/\u03b1v\u03b21 Integrins in Biliary Fibrosis"],"prefix":"10.1097","volume":"61","author":[{"given":"Yingying","family":"Ning","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna R.","family":"Schaub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Rotile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avery","family":"Boice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilknur","family":"Ay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3179-6537","authenticated-orcid":false,"given":"Peter","family":"Caravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,1]]},"reference":[{"key":"bib1-20260211","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"bib2-20260211","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm.2807","article-title":"Mechanisms of fibrosis: therapeutic translation for fibrotic disease","volume":"18","author":"Wynn","year":"2012","journal-title":"Nat Med"},{"key":"bib3-20260211","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41575-023-00807-x","article-title":"Hepatic inflammatory responses in liver fibrosis","volume":"20","author":"Hammerich","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"bib4-20260211","doi-asserted-by":"crossref","first-page":"100067","DOI":"10.1016\/j.jhepr.2020.100067","article-title":"Limitations of non-invasive tests for assessment of liver fibrosis","volume":"2","author":"Patel","year":"2020","journal-title":"JHEP Rep"},{"key":"bib6-20260211","doi-asserted-by":"crossref","first-page":"355ps16","DOI":"10.1126\/scitranslmed.aaf3936","article-title":"Imaging approaches to optimizemolecular therapies","volume":"8","author":"Weissleder","year":"2016","journal-title":"Sci Transl Med"},{"key":"bib7-20260211","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1172\/JCI122132","article-title":"Molecular imaging of fibrosis: recent advances and future directions","volume":"129","author":"Montesi","year":"2019","journal-title":"J Clin Invest"},{"key":"bib8-20260211","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/RLI.0000000000001096","article-title":"Multimodal imaging approach for tumor treatment response evaluation in the era of immunotherapy","volume":"60","author":"Lee","year":"2025","journal-title":"Invest Radiol"},{"key":"bib9-20260211","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00259-004-1675-x","article-title":"Molecular imaging and its biological applications","volume":"31","author":"Phelps","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib10-20260211","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI122216","article-title":"Peptide-based PET quantifies target engagement of PD-L1 therapeutics","volume":"129","author":"Kumar","year":"2019","journal-title":"J Clin Invest"},{"key":"bib11-20260211","doi-asserted-by":"crossref","first-page":"902","DOI":"10.2967\/jnumed.118.214726","article-title":"Immuno-PET imaging to assess target engagement: experience from 89Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors","volume":"60","author":"Menke-van der Houven van Oordt","year":"2019","journal-title":"J Nucl Med"},{"key":"bib12-20260211","doi-asserted-by":"crossref","first-page":"8171","DOI":"10.1002\/anie.200700700","article-title":"Collagen-targeted MRI contrast agent for molecular imaging of fibrosis","volume":"46","author":"Caravan","year":"2007","journal-title":"Angew Chem Int Ed Engl"},{"key":"bib13-20260211","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/RLI.0000000000000737","article-title":"Molecular magnetic resonance imaging of liver fibrosis and fibrogenesis is not altered by inflammation","volume":"56","author":"Dos Santos Ferreira","year":"2021","journal-title":"Invest Radiol"},{"key":"bib14-20260211","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1148\/radiol.2017170595","article-title":"CM-101: type I collagen-targeted MR imaging probe for detection of liver fibrosis","volume":"287","author":"Farrar","year":"2018","journal-title":"Radiology"},{"key":"bib15-20260211","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2013.06.026","article-title":"Molecular MRI of collagen to diagnose and stage liver fibrosis","volume":"59","author":"Fuchs","year":"2013","journal-title":"J Hepatol"},{"key":"bib16-20260211","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jhep.2015.04.029","article-title":"3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model","volume":"63","author":"Farrar","year":"2015","journal-title":"J Hepatol"},{"key":"bib17-20260211","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/hep.28930","article-title":"Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model","volume":"65","author":"Zhu","year":"2017","journal-title":"Hepatology"},{"key":"bib18-20260211","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/hep4.1193","article-title":"Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist","volume":"2","author":"Erstad","year":"2018","journal-title":"Hepatol Commun"},{"key":"bib19-20260211","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jhep.2020.06.020","article-title":"Advances in functional and molecular MRI technologies in chronic liver diseases","volume":"73","author":"Zhou","year":"2020","journal-title":"J Hepatol"},{"key":"bib20-20260211","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1148\/radiol.2020192118","article-title":"Advanced MRI of liver fibrosis and treatment response in a rat model of nonalcoholic steatohepatitis","volume":"296","author":"Zhou","year":"2020","journal-title":"Radiology"},{"key":"bib21-20260211","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/RLI.0000000000000731","article-title":"Molecular MR contrast agents","volume":"56","author":"Shuvaev","year":"2021","journal-title":"Invest Radiol"},{"key":"bib22-20260211","doi-asserted-by":"crossref","first-page":"eabq6297","DOI":"10.1126\/scitranslmed.abq6297","article-title":"Molecular MRI quantification of extracellular aldehyde pairs for early detection of liver fibrogenesis and response to treatment","volume":"14","author":"Ning","year":"2022","journal-title":"Sci Transl Med"},{"key":"bib23-20260211","doi-asserted-by":"crossref","first-page":"16553","DOI":"10.1021\/jacs.2c06231","article-title":"Dual hydrazine-equipped turn-on manganese-based probes for magnetic resonance imaging of liver fibrogenesis","volume":"144","author":"Ning","year":"2022","journal-title":"J Am Chem Soc"},{"key":"bib24-20260211","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"Dyson","year":"2018","journal-title":"Lancet"},{"key":"bib25-20260211","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s00535-023-02006-6","article-title":"Anti-integrin \u03b1v\u03b26 autoantibodies in patients with primary sclerosing cholangitis","volume":"58","author":"Yoshida","year":"2023","journal-title":"J Gastroenterol"},{"key":"bib26-20260211","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/hep.21849","article-title":"Role of alphav-beta-6 integrin in acute biliary fibrosis","volume":"46","author":"Wang","year":"2007","journal-title":"Hepatology"},{"key":"bib27-20260211","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jhep.2007.11.021","article-title":"Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies","volume":"48","author":"Popov","year":"2008","journal-title":"J Hepatol"},{"key":"bib28-20260211","doi-asserted-by":"crossref","first-page":"288ra79","DOI":"10.1126\/scitranslmed.aaa5094","article-title":"The alphav-beta-1 integrin plays a critical in vivo rolein tissue fibrosis","volume":"7","author":"Reed","year":"2015","journal-title":"Sci Transl Med"},{"key":"bib29-20260211","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/embor.2009.276","article-title":"Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing","volume":"11","author":"Margadant","year":"2010","journal-title":"EMBO Rep"},{"key":"bib30-20260211","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.bbadis.2012.10.005","article-title":"Integrin-mediated regulation of TGF\u03b2 in fibrosis","volume":"1832","author":"Henderson","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"bib31-20260211","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat Med"},{"key":"bib32-20260211","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41573-021-00284-4","article-title":"Emerging therapeutic opportunities for integrin inhibitors","volume":"21","author":"Slack","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"bib33-20260211","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12931-021-01863-0","article-title":"Dual inhibition of \u03b1v\u03b26 and \u03b1v\u03b21 reduces fibrogenesis in lung tissue explants from patients with IPF","volume":"22","author":"Decaris","year":"2021","journal-title":"Respir Res"},{"key":"bib34-20260211","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/S0168-8278(24)00606-8","article-title":"\u03b1v\u03b26 and \u03b1v\u03b21 integrin inhibitor bexotegrast in primary sclerosing cholangitis: updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC phase 2a trial","volume":"80","author":"Trauner","year":"2024","journal-title":"J Hepatol"},{"issue":"S1","key":"bib35-20260211","first-page":"S1536","article-title":"Dual \u03b1v\u03b26\/\u03b1v\u03b21 integrin inhibitor bexotegrast attenuates profibrogenic gene experssion across multiple pathologic cell types in human liver explant tissue with biliary fibrosis","volume":"78","author":"Schuab","year":"2023","journal-title":"Hepatology"},{"key":"bib36-20260211","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s11307-023-01845-2","article-title":"Optimization of an allysine-targeted PET probe for quantifying fibrogenesis in a mouse model of pulmonary fibrosis","volume":"25","author":"Shuvaev","year":"2023","journal-title":"Mol Imaging Biol"},{"key":"bib37-20260211","doi-asserted-by":"crossref","first-page":"e91506","DOI":"10.1172\/jci.insight.91506","article-title":"Molecular imaging of oxidized collagen quantifies pulmonary and hepatic fibrogenesis","volume":"2","author":"Chen","year":"2017","journal-title":"JCI Insight"},{"issue":"1\u20132","key":"bib38-20260211","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S1570-0232(03)00248-4","article-title":"Liquid chromatographic determination of hydroxyproline in tissue samples","volume":"791","author":"Hutson","year":"2003","journal-title":"J Chromatogr B"},{"key":"bib39-20260211","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/s41467-019-11863-w","article-title":"Evaluation of integrin alphav-beta-6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis","volume":"10","author":"Kimura","year":"2019","journal-title":"Nat Commun"},{"key":"bib40-20260211","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1007\/s00261-020-02677-2","article-title":"Collagen-targeted molecular imaging in diffuse liver diseases","volume":"45","author":"Zhou","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"bib41-20260211","first-page":"105","article-title":"Liver fibrosis: a clinical update","author":"Shipley","year":"2019","journal-title":"Hepatology"},{"key":"bib42-20260211","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.gastro.2020.05.046","article-title":"Why do so many nonalcoholic steatohepatitis trials fail?","volume":"165","author":"Ratziu","year":"2023","journal-title":"Gastroenterology"},{"key":"bib43-20260211","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"bib44-20260211","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"bib45-20260211","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.coph.2021.11.003","article-title":"Emerging drugs for the treatment of primary sclerosing cholangitis","volume":"62","author":"Abbas","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"bib46-20260211","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/liv.15157","article-title":"Integrins as a drug target in liver fibrosis","volume":"42","author":"Rahman","year":"2022","journal-title":"Liver Int"},{"key":"bib47-20260211","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/MOG.0000000000000995","article-title":"Integrins in biliary injury and fibrosis","volume":"40","author":"Schaub","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"key":"bib48-20260211","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1007\/s00261-021-03269-4","article-title":"Liver fibrosis assessment: MR and US elastography","volume":"47","author":"Ozturk","year":"2022","journal-title":"Abdom Radiol (NY)"},{"key":"bib49-20260211","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic Fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"key":"bib50-20260211","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/RLI.0000000000000952","article-title":"Single breath-hold 3-dimensional magnetic resonance elastography depicts liver fibrosis and inflammation in obese patients","volume":"58","author":"Darwish","year":"2023","journal-title":"Invest Radiol"},{"key":"bib51-20260211","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/RLI.0000000000001053","article-title":"Divalent manganese complexes as potential replacements for gadolinium-based contrast agents","volume":"59","author":"Caravan","year":"2024","journal-title":"Invest Radiol"},{"key":"bib52-20260211","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/RLI.0000000000001037","article-title":"A new era in magnetic resonance contrast media","volume":"59","author":"Runge","year":"2024","journal-title":"Invest Radiol"},{"key":"bib53-20260211","doi-asserted-by":"crossref","DOI":"10.1097\/RLI.0000000000001180","article-title":"Recent developments and future perspectives in magnetic resonance imaging and computed tomography contrast media","author":"Frenzel","year":"2025","journal-title":"Invest Radiol"},{"key":"bib54-20260211","doi-asserted-by":"crossref","first-page":"e2220036120","DOI":"10.1073\/pnas.2220036120","article-title":"Fast detection of liver fibrosis with collagen-binding single-nanometer iron oxide nanoparticles via T(1)-weighted MRI","volume":"120","author":"Zhang","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"bib55-20260211","first-page":"rs.3.rs-5349052","article-title":"Manganese-based type I collagen-targeting MRI probe for in vivo imaging of liver fibrosis","author":"Zhang","year":"2024","journal-title":"Res Sq [Preprint]"},{"key":"bib56-20260211","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1164\/rccm.202403-0636OC","article-title":"Bexotegrast in patients with idiopathic pulmonary fibrosis: the INTEGRIS-IPF clinical trial","volume":"210","author":"Lancaster","year":"2024","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Investigative Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLI.0000000000001202","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T12:00:29Z","timestamp":1770811229000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLI.0000000000001202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rli.0000000000001202","relation":{},"ISSN":["1536-0210"],"issn-type":[{"value":"1536-0210","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}